Patient Safety In Hospitals : An Overview
Keywords:
Ebola, Ebola Haemorrhagic Fever, EHFAbstract
Ebola is one of the most lethal virus that infects primates. This virus first recognised in 1976, when two unrelated Ebola Haemorrhagic Fever (EHF) outbreaks occurred in Yambuku & Nzara. It was named as EBOLA after the small river near the catholic mission of Yambuku, the epicentre of 1976 EHF outbreak. It belongs to the family Filoviridae in the order Mononegaviriales. Transmission human to human or animal to human through contact with infected blood or bodily fluids or by contact with contaminated medical equipment’s. Bats are considered the most likely natural reservoir of the EBOV. Typical infection runs its course within 14-21 days. Infection initially present with non specific symptoms such as fever, myalgia, malaise, headache, joint & muscle pain, abdominal pain, vomiting, diarrhea and loss of appetite are common. As the infection progresses patient exhibits bleeding and coagulation abnormalities. Laboratory diagnosis detection of viral antigen by ELISA or RT-PCR are useful. There is no FDA approved antiviral treatment for EHF. Supportive management palliative care has to be practiced.
Downloads
References
R. Siegel, et al, Tara’s Ebola site, [Honors Thesis]. Dept. of Human biology, Stanford University : 1 9 9 8 . http://web.stanford.edu/group/virus/filo/filo.html
J. J. Muyembe – Tamfum, S. Mulangu, j. Masumu, J. M. Kayembe, et al: Ebola virus outbreak in Africa: Past and present: Onderstpoor journal of Veterinary Research: 2012: 79(2): 451 – 458.
M A Casillas, AM Nyamathi, A Sosa, CL Wilder, et al: A current review of Ebola virus: Pathogenesis, Clinical presentation, and Diagnostic Assessment: Biological Research for Nursing: April 2003:4(4):268-275.
http: // en. wikipedia. org/w/index. php? title=Ebola_virus_disease
N Sullivan, ZY Yang, GJ Nabel : Minireview: Ebola Virus Pathogenesis: Implications for Vaccines & Therapies .;2003: Journal of virology: 77(18): 9733-9737.
A Sanchez, Z Yang, L Xu, GJ Nabel, et al: Biochemical analysis of secreted and virion glycoprotein of Ebola virus.; 1998: Journal of Virology: 72: 6442-6447.
ZY Yang, R Delgado, L Xu, RF Todd, et al: Distinct Cellular interaction of secreted and transmembrane Ebola virus glycoproteins: 1998: Science: 279: 1034 – 1037.
U Sterher, E West, H Bugany, HD Klenk, et al: Infection and activation of monocytes by Margburg & Ebola viruses. 2001: Journal of Virology: 75: 11-25-11033.
ZY Yang, HJ Duckers, NJ Sullivan, A Sanchez, et al: Identification of Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury .; 2000: Nat. Med. : 6: 886-889.
A Sanchez, AS Khan, SR Zaki, GJ Nabel, et al: Filoviridae: Margburg and Ebola Viruses; 2001: In. D. M. Knipe and P. M. Howely (ed.), Fields Virology. Lippioncott, Willams, Philadelphia. Pa.: 1279-1304.
Ito, HS Watanabe, A Takada, Y Kawaoka.: Ebola virus glycoprotein: proteolytic processing, acylation, cell trophism and detection of neutralizing antibodies.; 2001; Journal of Virology: 75: 1576-1580.
PB Jahrling, J Geisbert, JR Swearengen, GP Jaax, T Lewis, et al ; Passive immunization of Ebola virus – infected Cynomolgus monkeywith immunoglobulin from hyper immune horses. Arch. Virol. 1996: 11 (suppl.) 135-140.
Center for Disease Control and Prevention Special Pathogens Branch: Ebola Hemorrhagic fever. : 2002b:
L Borio, T Inglesby, CJ Peters, AL Schmaljohn, et al: Hemorrhagic fever viruses as biological weapons – medical and public health management.: 2002: JAMA: 287: 2391 – 2405.
Center for Disease Control and Prevention Special Pathogens Branch. : Ebola hemorrhagic fever table showing known cases and outbreaks, in chronological order. : 2002a.
World Health Organisation (WHO), WHO recommended guideline for epidemic preparedness and response: Ebola haemorrhagic fever (EHF). : 1997.
Published
How to Cite
Issue
Section
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.